UBS: Maintains "Buy" rating on HUTCHMED (00013), target price HK$29.5
Sovleplenib (a Syk inhibitor) has been approved in China via priority review for the treatment of ITP and wAIHA, which the bank views as positive and better than expected.
UBS released a research report stating that Sovleplenib (a Syk inhibitor) has been approved in China via priority review for the treatment of ITP and wAIHA, which the bank views as positive and better than expected. The bank maintains its "Buy" rating on HUTCHMED (00013) with a target price of HK$29.5.
The bank noted that Sovleplenib is China's first and only approved Syk inhibitor, with the approval supported by the ESLIM-01/02 studies. The bank estimates peak sales of US$327 million by 2035, versus market expectations of US$241 million. The next key focus will be updates on the overseas development strategy.
Related Articles

Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25042 intravitreal injection solution receives clinical trial approval

J.P. Morgan: Maintains TENCENT (00700) "Overweight" rating, target price HK$560

China Jushi Co., Ltd (600176.SH) has obtained a commitment letter from a financial institution for a special loan for share repurchase.
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25042 intravitreal injection solution receives clinical trial approval

J.P. Morgan: Maintains TENCENT (00700) "Overweight" rating, target price HK$560

China Jushi Co., Ltd (600176.SH) has obtained a commitment letter from a financial institution for a special loan for share repurchase.






